| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,100 | ₹1.05 0% | 00% |
| - | - | 4,200 | ₹0.9 0% | 3,1250% |
| - | - | 4,300 | ₹4 0% | 2500% |
| - | - | 4,350 | ₹7.2 0% | 1,5000% |
| 2500% | ₹418 0% | 4,400 | ₹1.8 -62.5% | 3,000-17.24% |
| - | - | 4,450 | ₹12.05 0% | 1,6250% |
| - | - | 4,500 | ₹6 -50% | 23,62518.12% |
| 3750% | ₹375.6 0% | 4,550 | ₹16.45 0% | 1,3750% |
| 1,75027.27% | ₹334.25 20.36% | 4,600 | ₹8.4 -64.92% | 13,875-33.92% |
| 1250% | ₹248.05 -12.78% | 4,650 | ₹12 -70.18% | 2,625-27.58% |
| 7,50030.43% | ₹260 34.71% | 4,700 | ₹16.65 -64.57% | 20,125-13.44% |
| 7,8750% | ₹229 43.34% | 4,750 | ₹28.3 -55.39% | 9,7501.29% |
| 28,500-33.72% | ₹187.2 36.74% | 4,800 | ₹37.05 -55.99% | 41,750-5.91% |
| 16,250-52.20% | ₹153.1 38.86% | 4,850 | ₹51 -51.81% | 16,750-5.63% |
| 41,750-30.27% | ₹124.8 41.17% | 4,900 | ₹72.55 -43.82% | 27,75016.84% |
| 11,62543.07% | ₹99 47.76% | 4,950 | ₹173.2 0% | 2,0000% |
| 1,05,750-7.13% | ₹76.6 39.78% | 5,000 | ₹121 -39.28% | 27,750-9.38% |
| 8,5001.49% | ₹57.5 36.9% | 5,050 | ₹151.95 -27.48% | 75020% |
| 40,875-0.60% | ₹44 34.96% | 5,100 | ₹184.5 -38.79% | 12,8750% |
| 2,1250% | ₹24.1 10.55% | 5,150 | ₹290.4 0% | 3750% |
| 26,000-3.70% | ₹23.9 37.35% | 5,200 | ₹317.5 0% | 1250% |
| 750200% | ₹15.8 146.87% | 5,250 | - | - |
| 11,375-5.20% | ₹11.85 12.85% | 5,300 | ₹470 0% | 3750% |
| 3,875-11.42% | ₹8.35 0.6% | 5,350 | - | - |
| 5,375-14% | ₹6.6 -10.2% | 5,400 | ₹510 0% | 2500% |
| 1,7500% | ₹4.8 0% | 5,450 | - | - |
| 7,1250% | ₹3 0% | 5,500 | ₹677.2 0% | 5000% |
| 1,2500% | ₹7.1 0% | 5,550 | - | - |
| 5,0000% | ₹2.9 0% | 5,600 | - | - |
| 4,6250% | ₹2.5 0% | 5,700 | - | - |
| 6,0000% | ₹1 0% | 5,800 | ₹855 -10.47% | 125-50% |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
